ADVA announces record revenues for Q1 2022
ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for Q1 2022 ended on March 31, 2022. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005984/en/
Uli Dopfer, CFO, ADVA (Photo: Business Wire)
Q1 2022 financial summary 1
|
(in thousands of EUR) |
|
Q1 2022 |
|
Q1 2021 |
|
Change |
|
Q4 2021 |
|
Change |
|
Revenues |
|
170,498 |
|
144,473 |
|
18.0 % |
|
157,713 |
|
8.1% |
|
Pro forma gross profit |
|
53,405 |
|
55,345 |
|
(3.5)% |
|
56,072 |
|
(4.8)% |
|
in % of revenues |
|
31.3% |
|
38.3% |
|
(7.0) pp |
|
35.6% |
|
(4.3) pp |
|
Pro forma EBIT |
|
7,812 |
|
12,860 |
|
(39.3)% |
|
14,362 |
|
(45.6)% |
|
in % of revenues |
|
4.6% |
|
8.9% |
|
(4.3) pp |
|
9.1% |
|
(4.5) pp |
|
Operating income 2 |
|
5,976 |
|
11,573 |
|
(48.4)% |
|
11,190 |
|
(46.6)% |
|
Net income |
|
6,179 |
|
11,228 |
|
(45.0)% |
|
17,511 |
|
(64.7)% |
|
(in thousands of EUR) |
|
Mar. 31, 2022 |
|
Mar. 31, 2021 |
|
Change |
|
Dec. 31, 2021 |
|
Change |
|
Cash and cash equivalents |
|
73,002 |
|
79,060 |
|
(7.7)% |
|
108,987 |
|
(33.0)% |
|
Net cash (+)/net debt (-) |
|
763 |
|
(10,626) |
|
n/a |
|
36,166 |
|
(97.9)% |
|
Net working capital |
|
164,402 |
|
125,785 |
|
30.7% |
|
128,954 |
|
27.5% |
1 Potential inconsistencies in the table values are based on rounding differences.
2 Q1 2022 including EUR 0.5 million and Q4 2021 including EUR 1.6 million extraordinary expenses.
Q1 2022 IFRS financial results
Revenues in Q1 2022 reached EUR 170.5 million, up by 8.1% from EUR 157.7 million in Q4 2021, also considerably up by 18.0% compared to EUR 144.5 million in Q1 2021. The increase in revenues for Q1 2022 is predominantly driven by a growth in demand from communication service providers (CSPs) and internet content providers (ICPs).
Pro forma gross profit in Q1 2022 decreased by 4.8%, reaching EUR 53.4 million (31.3% of revenues) compared to EUR 56.1 million (35.6% of revenues) in Q4 2021 and decreased by 3.5% compared to EUR 55.3 million (38.3% of revenues) reported in Q1 2021. The reduction in gross profit in relation to revenues is mainly attributable to increased purchasing costs due to the semiconductor crisis and a stronger US Dollar.
Pro forma EBIT for Q1 2022 was EUR 7.8 million (4.6% of revenues) and decreased by 45.6% compared to EUR 14.4 million (9.1% of revenues) reported in Q4 2021 and declined by 39.3% from EUR 12.9 million (8.9% of revenues) in Q1 2021.
Operating income for Q1 2022 of EUR 6.0 million decreased by 46.6% from EUR 11.2 million reported for Q4 2021 and decreased by 48.4% from EUR 11.6 million in Q1 2021. Operating income for Q1 2022 was impacted by extraordinary expenses in connection with the announced merger with Adtran, amounting to EUR 0.5 million (Q4 2021: EUR 1.6 million and Q1 2021: EUR 0).
Net income reached EUR 6.2 million in Q1 2022 and significantly decreased by 64.7% from EUR 17.5 million in Q4 2021 and decreased by 45.0% from EUR 11.2 million in Q1 2021.
The company’s cash and cash equivalents totaled EUR 73.0 million, representing a significant decrease of EUR 36.0 million compared to EUR 109.0 million at the end of Q4 2021. Year-over-year cash and cash equivalents decreased by EUR 6.1 million from EUR 79.1 million at the end of Q1 2021. The company invested non-operating cash in measures to secure delivery.
Net cash at the end of Q1 2022 stood at EUR 0.8 million compared to a net cash position of EUR 36.2 million at the end of Q4 2021 and a net debt position of EUR 10.6 million at the end of Q1 2021.
At quarter-end, net working capital totaled EUR 164.4 million and increased by EUR 35.4 million compared to EUR 129.0 million at the end of Q4 2021 and increased by EUR 38.6 million compared to EUR 125.8 million at the end of Q1 2021. The higher net working capital compared to the year-ago quarter is mainly attributable to increased inventory levels to secure the supply chain.
Management commentary
“We have good momentum and started well in this new business year. The expansion of communications networks is progressing rapidly and is fueled by public funding programs in many regions and countries. This environment should continue to positively impact demand for our products for the foreseeable future,” said Brian Protiva, CEO of ADVA. “Our investments in innovation in recent years have provided us with an outstanding, differentiated portfolio of solutions with which we will gain market share. The transformation of our business towards growth markets with a higher proportion of software and services and more verticalization is progressing well. In addition, the merger with Adtran will open up completely new opportunities for us in the USA, Europe and the global market.”
“Considering the extremely difficult external conditions, the past quarter was a strong start to the new 2022 financial year. We were able to increase our revenues by an exceptional 18% compared to the year-ago quarter; unfortunately, however, our success was limited by the ongoing semiconductor crisis. We certainly feel the, in parts, extreme cost increase of components as well as the global inflation in general. Nevertheless, we were able to achieve comparatively good profitability with a pro forma EBIT margin of 4.6%,” commented Uli Dopfer, CFO of ADVA. “Our exceptional solid balance sheet has enabled us to invest non-operating cash in our inventories, securing the supply chain. Further component shortages and higher costs are expected as the year progresses. However, we are confident that we also will master this challenge well.
2022 financial outlook
For the fiscal year 2022, ADVA expects revenues to be in the range of EUR 650 million and 700 million and a pro forma EBIT of between 6.0% and 10.0% of revenues.
The company will publish its financial results for Q2 2022 on July 28, 2022.
Conference call details
ADVA will hold a conference call for analysts and investors today, April 28, 2022, to discuss the Q1 2022 results. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.
A corresponding presentation is available on ADVA’s website:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls
The complete quarterly statement 3M 2022 (January – March) is available as a PDF here:
https://www.adva.com/en/about-us/investors/financial-results/financial-statements
A replay of the call will be available here:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls
Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.
Use of pro forma financial information
ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, non-recurring expenses related to M&A and restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005984/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Steven Williams
t +49 89 890 66 59 18
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 05:35:00 EET | Press release
Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through its partners by the end of October 2025, marking a threefold increase compared to the same period in 2024, with MSMEs among the key segments driving this growth. International Finance Corporation estimates a US$8 trillion financing gap for MSMEs in emerging markets and developing economies. With global platforms, from e-commerce to food delivery, entering emerging markets and local platforms in these markets continue to scale, many are looking to offer tailored credit services to better support MSMEs operating on their ecosystems. Doin
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 05:00:00 EET | Press release
Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in real-time global treasury management. It has already supported a successful H
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo ™ 300mg18.11.2025 04:51:00 EET | Press release
The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These improvements may contribute to an enhanced treatment journey for patients by helping reduce the disease burden they face throughout their care. Given its distinctive product profile, Omlyclo™ 300mg has the potential to become an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
